RxDoctor Payments Data

Bradley Taylor, APRN

Family · Paducah, KYNPI 1922529080

Payments from drug & device makers

$6,733in general payments, 2019–2025

Across 302 payments — averaging $22.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Boston Scientific$1K
  • Collegium Pharmaceutical, Inc.$1K
  • Abbott$598
  • Si-bone, Inc.$453
  • Amgen$432
  • plus $1K from 14 others

What the payments were for

  • Food & beverage$6,719100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,733 in reported general payments places this provider in the 95th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$1,339
Medicare patients
14
Services billed
15

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate50$80,662
BelbucaBuprenorphine Hcl107$78,488
UbrelvyUbrogepant25$31,308
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,331$26,285
Pregabalin708$21,892
Buprenorphine62$16,517
Gabapentin1,326$15,526
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl56$15,524
ZtlidoLidocaine19$14,358
LyricaPregabalin13$11,025
MovantikNaloxegol Oxalate23$9,049
Celecoxib221$8,019
Lidocaine70$6,020
Tizanidine Hcl561$4,910
Cyclobenzaprine Hcl430$2,979

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt, Lyrica$96$91,68763 claims
Collegium Pharmaceutical, Inc.Belbuca$1,022$78,488107 claims
AbbVieUbrelvy$418$31,30825 claims
Scilex Pharmaceuticals Inc.Ztlido$112$14,35819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,374 family providers in Kentucky.

Other family in Paducah

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →